首页> 美国政府科技报告 >Discordant Results from Reverse Sequence Syphilis Screening - Five Laboratories, United States, 2006-2010. Morbidity and Mortality Weekly Report, Vol. 60, No. 5, February 11, 2011
【24h】

Discordant Results from Reverse Sequence Syphilis Screening - Five Laboratories, United States, 2006-2010. Morbidity and Mortality Weekly Report, Vol. 60, No. 5, February 11, 2011

机译:反向序列梅毒筛查的不一致结果 - 美国五个实验室,2006-2010。发病率和死亡率周报,Vol。 2011年2月11日,第60期,第5期

获取原文

摘要

CDC recommends syphilis serologic screening with a nontreponemal test, such as the rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL) test, to identify persons with possible untreated infection; this screening is followed by confirmation using one of several treponemal tests. Recently, the availability of automatable treponemal enzyme and chemiluminescence immunoassays (EIA/CIA) has led some laboratories to adopt a reverse sequence of screening in which a treponemal EIA/CIA is performed first, followed by testing of reactive sera with a nontreponemal test. To better understand the performance of reverse sequence screening for syphilis, CDC analyzed data from five laboratories that used reverse sequence screening during 2006-2010. This report describes the results of that analysis, which indicated that among sera reactive on initial screening with a treponemal EIA/CIA, 56.7% had a nonreactive RPR test. Among these discordant sera, 31.6% also were nonreactive by treponemal testing using Treponema pallidum particle agglutination (TP-PA) or fluorescent treponemal antibody absorbed (FTA-ABS) tests. Among discordant sera, the rate of nonreactive confirmatory treponemal tests was 2.9 times higher in a population with low prevalence of syphilis, suggesting that the low-prevalence population had a higher percentage of false-positive test results.

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号